Skip to Content

Albiglutide Side Effects

In Summary

Commonly reported side effects of albiglutide include: injection site reaction, diarrhea, and nausea. Other side effects include: vomiting. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to albiglutide: subcutaneous powder for solution

In addition to its needed effects, some unwanted effects may be caused by albiglutide. In the event that any of these side effects do occur, they may require medical attention.

Major Side Effects

You should check with your doctor immediately if any of these side effects occur when taking albiglutide:

  • Bloating
  • chills or fever
  • darkened urine
  • fast heartbeat
  • loss of appetite
  • nausea, vomiting, or indigestion
  • pains in the stomach, side, or abdomen, possibly radiating to the back
Incidence not known:
  • Anxiety, irritability, or mood changes
  • blurred vision
  • cold sweats
  • confusion
  • difficulty with breathing or swallowing
  • dizziness
  • headache
  • increased hunger
  • shakiness
  • skin itching, rash, or redness
  • slurred speech
  • swelling of the face, throat, or tongue
  • unusual tiredness or weakness

Minor Side Effects

Some of the side effects that can occur with albiglutide may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:
  • Body aches or pain
  • cough
  • diarrhea
  • ear congestion
  • loss of voice
  • muscle pain or stiffness
  • pain in the joints
  • pain or tenderness around the eyes and cheekbones
  • skin reactions, warmth, or redness at the injection site
  • sneezing
  • stuffy or runny nose

For Healthcare Professionals

Applies to albiglutide: subcutaneous powder for injection


Very common (10% or more): Diarrhea (13.1%), nausea (11.1%),
Common (1% to 10%): Vomiting, gastroesophageal reflux disease, dyspepsia, constipation
Uncommon (0.1% to 1%): Appendicitis, acute pancreatitis, intestinal obstruction[Ref]

The incidence of pancreatitis (adjudicated as likely to be related to therapy) in clinical trials was 0.3% compared with 0% for placebo and 0.1% for comparators (e.g., liraglutide, pioglitazone, glimepiride, sitagliptin, and insulin glargine) with or without background antidiabetic therapy (e.g. metformin)

Gastrointestinal events occurred more frequently with this drug compared to comparators (38% versus 32%). Diarrhea (13% vs 9%), nausea (12% vs 11%), vomiting (5% vs 4%), and constipation (5% vs 4%) were the most commonly reported , and the majority of events occurred within the first 6 months.[Ref]


Very common (10% or more): Positive test for anti-albiglutide antibodies[Ref]


Very common (10% or more): Injection site reaction (up to 15%)
Common (1% to 10%): Injection site hematoma, erythema, rash, and/or pruritus
Uncommon (0.1% to 1%): Injection site hypersensitivity and/or hemorrhage[Ref]


Very common (10% or more): Hypoglycemia (when used in combination with insulin or sulfonylurea)
Common (1% to 10%): Hypoglycemia (when used as monotherapy in combination with metformin or pioglitazone)[Ref]


Very common (10% or more): Back pain (6.7%), arthralgia (6.6%)[Ref]


Very common (10% or more): Influenza (5.2%)[Ref]


Very common (10% or more): Upper respiratory tract infection (14.2%), cough (6.9%), sinusitis (6.2%)
Common (1% to 10%): Pneumonia[Ref]


Common (1% to 10%): Atrial fibrillation
Uncommon (0.1% to 1%): Atrial flutter[Ref]


Common (1% to 10%): Increased ALT, gamma glutamyltransferase[Ref]


Frequency not reported: Pruritus, rash, dyspnea[Ref]


Frequency not reported: Risk of Thyroid C-cell Tumors[Ref]

Medullary thyroid cancer (MTC) was diagnosed in 1 patient receiving this drug and 1 patient receiving placebo across 8 phase 3 clinical trials. Both of these patients had markedly elevated serum calcitonin levels at baseline.[Ref]


Frequency not reported: Renal impairment[Ref]


1. "Product Information. Tanzeum (albiglutide)." GlaxoSmithKline, Research Triangle Park, NC.

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Not all side effects for albiglutide may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.